B6E.SG - Swedish Orphan Biovitrum AB
| Previous Close | 18.89 |
| Open | 18.86 |
| Bid | 18.94 x 100000 |
| Ask | 19.10 x 100000 |
| Day's Range | 18.81 - 18.86 |
| 52 Week Range | 18.01 - 23.82 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Annals of Rheumatic Diseases Publishes Results from Phase 2 Study of emapalumab in Patients with Secondary HLH/Macrophage Activation Syndrome
Results showed that MAS remission was seen in 13 of 14 patients with sHLH/MAS receiving emapalumab who had an inadequate response to high-dose glucocorticosteroidsWALTHAM, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®) (STO:SOBI), today announced that the Annals of Rheumatic Diseases has published results from an open-label, single-arm, multicenter phase 2 study evaluating the safety and efficacy of emapalumab, an
- GlobeNewswire
Sobi Receives Approval from Health Canada for Empaveli™ (pegcetacoplan) for the Treatment of Certain Patients with Paroxysmal Nocturnal Hemoglobinuria
The first targeted C3 therapy approved in CanadaApproval based on results from head-to-head PEGASUS phase 3 study where Empaveli™ demonstrated superiority to eculizumab in improving hemoglobin levels1On trial, transfusion avoidance was achieved by 85.4% patients in the Empaveli group versus 15.4% in the eculizumab group1 WALTHAM, Mass., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®) (STO:SOBI), announced today that Health
- GlobeNewswire
U.S. Food and Drug Administration Issues Emergency Use Authorization for KINERET® (anakinra) for the Treatment of COVID-19-Related Pneumonia
Early treatment with KINERET reduced disease progression by 64 percent in hospitalized COVID-19 patientsi WALTHAM, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for KINERET® (anakinra) for the treatment of Coronavirus Disease 2019 (COVID-19) in adult patients who are hospitalized with positive results of d
- GlobeNewswire
Sobi to Present Data from REAL-HLH Study at the ACR Convergence 2022 Meeting
Data presented from the REAL-HLH study; the first study of patients treated with Gamifant in a real-world clinical settingWALTHAM, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of the Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI), a specialized international biopharmaceutical company transforming the lives of people with rare diseases, today announced a presentation from the REAL-HLH study – a chart review study which assessed real-world treatm
- Business Wire
ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories
LAUSANNE, Switzerland, July 08, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the United States, greater China, Singapore and Japan. The Marketing Authorization Application (MAA) for ZYNLONTA was validated by the European Medicines Agency (EMA) at the end of October 2021, and orphan d
- GlobeNewswire
Sobi Announces Launch of the INTO-HLH Registry, a Disease Registry for Patients with Hemophagocytic Lymphohistiocytosis (HLH)
INTO-HLH Registry serves as the first in-depth disease registry for the HLH medical and patient community in North AmericaWALTHAM, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Sobi® North America today announced the launch of the INTO-HLH Registry, a new disease registry for patients with hemophagocytic lymphohistiocytosis (HLH). The INTO-HLH Registry (Insight into the Natural history and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis) will enroll pediatric and adult patients with HLH, a r
